Quantcast

Latest Nycomed Stories

2010-07-19 03:21:00

ZURICH, July 19, 2010 /PRNewswire/ -- - Nycomed's Protonix(R) Patent Found Infringed and not Obvious - U.S. District Court for the District of New Jersey has Upheld Jury Findings - Nycomed Will Continue to Vigorously Pursue its Damage Claims Nycomed announced today that Judge Jose L. Linares of the U.S. District Court for the District of New Jersey has confirmed the jury verdict in favor of Nycomed and Pfizer Inc. The decision upholds the jury verdict issued on...

2010-07-06 09:19:00

MELVILLE, N.Y., July 6 /PRNewswire/ -- E. Fougera & Co., a leading specialty pharmaceutical manufacturer, announced it has received first generic approval from the FDA for Adapalene Cream 0.1% (Rx). Fougera's Adapalene Cream 0.1% is rated AB, generically equivalent to Differin® by Galderma Pharmaceuticals. According to industry data, U.S. sales of the brand named product in 2009 exceeded $55 million. This approval also marks the fourth product approval that the FDA...

2010-06-16 15:30:00

CUPERTINO, Calif., June 16 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today results from a European Phase IIb hysterectomy clinical trial conducted by Nycomed of POSIDUR(TM) (also known as SABER(TM)-bupivacaine or Optesia(TM) in the E.U.), a proprietary product under development for the treatment of post-surgical pain. (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO) This hysterectomy...

2010-06-10 08:13:00

GLASGOW, Scotland, June 10, 2010 /PRNewswire/ -- - Experts concerned that inadequate treatment strategies make cancer patients suffer unnecessarily Further results from the European Survey of Breakthrough Cancer Pain(1) were presented for the first time today at the 6th Research Congress of the European Association for Palliative Care (EAPC) in Glasgow. The survey, which is the first international survey to look in detail at breakthrough cancer pain (BTCP) from a patient...

2010-06-08 07:00:00

BETHESDA, Md., June 8 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that Christian Itin, Ph.D., Micromet's President and Chief Executive Officer, will present a corporate overview at three upcoming investor conferences: Jefferies 2010 Global Life Sciences Conference Wednesday, June 9, at 2 PM ET Grand Hyatt, New...

2010-05-10 15:05:00

CUPERTINO, Calif., May 10 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2010. Total revenues were $7.7 million for the three months ended March 31, 2010 and $6.2 million for the three months ended March 31, 2009. Net loss for the three months ended March 31, 2010 was $6.6 million, compared to a net loss of $8.7 million for the same period in 2009. (Logo:...

2010-02-25 16:13:00

MELVILLE, N.Y., Feb. 25 /PRNewswire/ -- E. Fougera & Co., a leading specialty pharmaceutical manufacturer, today announced it has received first generic approval from the FDA for Imiquimod Cream 5% (Rx). Fougera's Imiquimod Cream 5% is rated AB, generically equivalent to Aldara® by Graceway Pharmaceuticals and substitutable for all indications. According to industry data, U.S. sales of the brand named product in 2009 exceed $360 million. "Fougera's commitment to...

2010-02-25 15:02:00

BETHESDA, Md., Feb. 25 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) today announced that the Company will participate in the 2010 RBC Capital Markets Healthcare Conference, to be held March 2 - 3, 2010 in New York City. Christian Itin, Ph.D., the Company's President and CEO, will participate in a panel discussion titled New Targets in Cancer Therapy on March 2, 2010 at 8:00 AM ET. The panel discussion will be webcast live and may be accessed at:...

2010-02-24 15:05:00

CUPERTINO, Calif., Feb. 24 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2009. Total revenues were $4.9 million for the three months ended December 31, 2009 and $7.7 million for the three months ended December 31, 2008. Net loss for the three months ended December 31, 2009 was $9.0 million, compared to a net loss of $18.4 million for the same period in 2008 which included a $13.5 million...

2010-02-22 07:30:00

CUPERTINO, Calif., Feb. 22 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Nycomed and DURECT have amended the Development and License Agreement entered into between the parties in 2006 covering the development and commercialization of POSIDUR(TM) (also known as SABER(TM)-Bupivacaine or OPTESIA(TM)), an investigational drug for the treatment of post-surgical pain. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO) The amendment provides DURECT...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related